People living with neurological, inflammatory and fibrotic diseases are at the center of Contineum’s mission.
Your contributions are important to our success and our goal of developing safe and effective treatments for serious diseases including idiopathic pulmonary fibrosis (IPF), chronic pain and multiple sclerosis (MS).
Patient Advocacy
We partner with advocacy and research groups to increase trial awareness in the patient communities we strive to serve.
You can potentially help change how serious neurological, inflammatory and fibrotic diseases are treated. An important part of developing new therapies is investigating them through clinical trials. Trials help us to better understand how treatments work, how effective they are, and if there are any risks or side effects. Your doctor will help you decide if taking part in a clinical trial is the right option for you.
Therapeutic Areas
in Focus
Idiopathic pulmonary fibrosis (IPF)
IPF is the most common type of idiopathic interstitial lung disease. More than 250,000 Americans are living with pulmonary fibrosis (PF), and IPF is one of the most common forms of PF. The prevalence of PF and interstitial lung disease is on the rise, with more than 50,000 new cases diagnosed annually.
Multiple sclerosis (MS)
MS is an unpredictable disease of the central nervous system. MS disrupts the flow of information within the brain, and between the brain and body. An individual’s experience with MS may change from day to day and year to year. Almost 1 million people in the United States have received a diagnosis of multiple sclerosis.
Ongoing clinical trials
View more information on our trials
Additional resources, patient advocacy groups, community partners
